---
date: "2021-04-10T00:00:00Z"
external_link: ""
image:
  focal_point: Smart
  preview_only: true
summary: WIndow-of-opportunity clinical trial platform for evaluation of novel treatment strategies in REnal cell cancer
tags:
- Ongoing-trial
- WIRE
title: WIRE
url_code: ""
url_pdf: ""
url_slides: ""
url_video: ""
---

WIRE is funded by [AstraZeneca](https://www.astrazeneca.co.uk/), led by CI [Grant Stewart](https://surgery.medschl.cam.ac.uk/staff/stewart/), and sponsored by [Cambridge University Hospitals NHS Foundation Trust](https://www.cuh.nhs.uk/).

It is a a phase 2, multi-arm, multicentre, non-randomised, proof-of-mechanism trial using a Bayesian adaptive design.

You can find out more [here](https://cctu.org.uk/portfolio/cancer/trials-in-setup/wire), or from WIRE's registration on [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT03741426).
